Voronoi’s Brain-Permeable NSCLC Candidate Attracts ORIC To Major Deal
$350m Total Value
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
